Thermo Fisher Scientific Inc. $TMO Shares Acquired by Hardy Reed LLC

Key Points

• Hardy Reed LLC significantly increased its stake in Thermo Fisher Scientific Inc. by 96.9% during the second quarter, owning 5,060 shares valued at over $2 million.
• Insider selling activity has been noted, with executives selling a total of 30,066 shares worth approximately $14.18 million over the last quarter.
• The company reported earnings per share of $5.36 for the last quarter, exceeding expectations and predicting a fiscal year EPS of up to 22.84.

Hardy Reed LLC raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 96.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,060 shares of the medical research company's stock after buying an additional 2,490 shares during the period. Hardy Reed LLC's holdings in Thermo Fisher Scientific were worth $2,052,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. CBIZ Investment Advisory Services LLC raised its holdings in Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock worth $28,000 after purchasing an additional 33 shares in the last quarter. Anderson Financial Strategies LLC acquired a new stake in shares of Thermo Fisher Scientific in the first quarter valued at $30,000. Keystone Global Partners LLC bought a new position in Thermo Fisher Scientific during the first quarter valued at about $31,000. IMA Advisory Services Inc. acquired a new position in Thermo Fisher Scientific during the first quarter worth about $35,000. Finally, Smallwood Wealth Investment Management LLC acquired a new stake in Thermo Fisher Scientific in the 1st quarter valued at about $37,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares in the company, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CAO Joseph R. Holmes sold 385 shares of the business's stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the sale, the chief accounting officer directly owned 2,319 shares of the company's stock, valued at $1,142,408.97. This represents a 14.24% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 30,066 shares of company stock valued at $14,182,963. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Price Performance

NYSE TMO opened at $544.44 on Tuesday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The firm has a market capitalization of $205.59 billion, a price-to-earnings ratio of 31.49, a price-to-earnings-growth ratio of 2.95 and a beta of 0.77. The company has a 50 day simple moving average of $483.77 and a 200-day simple moving average of $446.95. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $610.97.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same quarter last year, the business posted $5.37 EPS. The company's revenue for the quarter was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be issued a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio is currently 9.95%.

Wall Street Analyst Weigh In

TMO has been the topic of a number of research reports. Weiss Ratings reiterated a "hold (c-)" rating on shares of Thermo Fisher Scientific in a report on Saturday, September 27th. Royal Bank Of Canada set a $561.00 price target on Thermo Fisher Scientific and gave the company an "outperform" rating in a report on Tuesday, September 2nd. HSBC reissued a "hold" rating and set a $510.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Hsbc Global Res downgraded Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 24th. Finally, Robert W. Baird lifted their price target on Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a research note on Thursday, July 24th. Fifteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of "Moderate Buy" and a consensus target price of $585.37.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.